MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ccd.31686

Медицинская библиотека · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025

Bioprosthetic Valve Fracturing in Valve-in-Valve TAVI: Clinical and Echocardiographic Outcomes in Failing Perimount Aortic Bioprostheses-A Multicenter Registry.

Ruge Hendrik, Burri Melchior, Schreyer Julia, Georgescu Teodora-Cristiana, Frank Derk, Kim Won-Keun, de Backer Ole, Beyer Martin, Schäfer Andreas, Fraccaro Chiara, Tarantini Giuseppe, Xhepa Erion, Joner Michael, Krane Markus, Covarrubias Héctor Alfonso Alvarez

СтатьяМногоцентровое исследованиеСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Data comparing clinical and hemodynamic outcomes of bioprosthetic valve fracturing (BVF) and "standard"-postdilatation during valve-in-valve transcatheter heart valve implantation (ViV-TAVI) are lacking. The authors aimed to analyze hemodynamic and clinical outcomes of BVF compared to "standard"-postdilatation during ViV-TAVI.

METHODS

The REDUCE registry included patients who underwent ViV-TAVI within a Perimount surgical aortic valve bioprosthesis (Edwards Lifesciences, USA). Procedures were categorized to no postdilatation, "standard"-postdilatation and BVF. Hemodynamic and clinical outcomes at 30 days were collected and compared. A linear regression model was built to predict mean aortic gradient after ViV-TAVI.

RESULTS

A total of 240 patients from six European sites were included. Median age was 78 years [IQR 70; 83], logistic EuroSCORE calculated 20.0%[IQR 12.2; 33.1] and 159 patients (66%) were male. One hundred fourty-four Perimount valves (60%) had a true internal diameter (ID) ≤ 21 mm. Self-expanding valves (SEV) and ballon-expandable valves (BEV) were used in 60% and 40% of cases, respectively. One hundred sixteen procedures (48%) were executed without postdilatation, in 88 procedures (37%) "standard"-postdilatation and in 36 procedures (15%) BVF was used. 30-day survival was 93.3%. VARC-3 device success at 30 days was 71%. A multivariable regression analysis of the mean aortic gradient after ViV-TAVI showed a significant association with surgical valve size (-0.84 mmHg, p = 0.001; per 1 mm surgical valve size increase), execution of postdilatation (-3.25 mmHg, p = 0.007) and type of transcatheter heart valve (SEV: -7.31 mmHg, p < 0.001).

CONCLUSIONS

When performing ViV-TAVI within a Perimount surgical aortic bioprosthesis with a true ID ≤ 21 mm, the hemodynamic valve performance is most optimal when implanting a SEV-TAV and when postdilating the TAV-in-SAV complex. BVF did not result in superior hemodynamics compared to "standard"-postdilatation.

Для цитирования: Ruge Hendrik, Burri Melchior, Schreyer Julia, Georgescu Teodora-Cristiana, Frank Derk, Kim Won-Keun, de Backer Ole, Beyer Martin, Schäfer Andreas, Fraccaro Chiara, Tarantini Giuseppe, Xhepa Erion, Joner Michael, Krane Markus, Covarrubias Héctor Alfonso Alvarez. Bioprosthetic Valve Fracturing in Valve-in-Valve TAVI: Clinical and Echocardiographic Outcomes in Failing Perimount Aortic Bioprostheses-A Multicenter Registry.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2025. DOI: 10.1002/ccd.31686.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.